Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK; Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 22 Jun 2022 According to a Food and Drug Administration media release, the Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients greater than equal to 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
    • 26 Aug 2021 Results published in the Journal of Thoracic Oncology
    • 02 Jul 2021 Results (n=1076) of pooled analysis charactering the incidence, patterns and management of pyrexia in patients receiving dabrafenib plus trametinib in clinical trials (NCT01336634, NCT01682083, NCT01584648, NCT01597908) published in the European Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top